糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

阿卡波糖治疗糖耐量减低临床观察

将初诊96例IGT患者随机分为对照组46例,给予饮食运动指导。治疗组50例,在饮食运动的基础上给予阿卡波糖50mg口服,一日2～3次,连续18周,观察体重指数（BMI）、空腹血糖（FBG）、餐后2小时血糖（P2hBG）、糖化血红蛋白（HbAIC）、胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白（HDL—C）、低密度脂蛋白（LDL—C）。结果：对照组干预前后各项指数无明显变化（P〉0．05）,治疗组与对照组比较除HDL—C上升外其他指标均明显下降。结论：阿卡波糖治疗IGT减低疗效确切并能明显改善血脂代谢。     

葡萄糖耐量受损与冠心病

葡萄糖耐量受损（IGT）与冠心病关系密切,显著地影响冠心病的发病和转归。本文介绍餐后血糖定义及状态、监测及适应证、IGT的检出率与相关因素、对心血管系统的危害、干预措施和效果。